


# The IL-36 pathway and pustular psoriasis

The interleukin-36 (IL-36) pathway plays an important role in inflammation.<sup>1</sup>

IL-36 cytokines are expressed by, and act upon, various types of cells – such as keratinocytes, epithelial cells and immune cells – and work together in balance to regulate the inflammatory response.<sup>2-5</sup>


## IL-36 PATHWAY ACTIVATION

IL-36 agonists bind to the IL-36 receptor to activate the pathway and stimulate the inflammatory response, including the recruitment and activation of immune cells.




## IL-36 PATHWAY INHIBITION

The IL-36 receptor antagonist (IL-36RA) binds to the IL-36 receptor to block signaling and suppress the inflammatory response.



## DYSFUNCTION OF THE IL-36 PATHWAY: a key driver of pustular psoriasis

Uncontrolled inflammatory signalling, resulting from IL-36 receptor antagonist (IL-36RA) dysfunction or over-expression of IL-36 agonists, can lead to autoinflammatory skin diseases, such as generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP) – types of pustular psoriasis.<sup>2,5-8</sup>



While pustular psoriasis and plaque psoriasis are distinct conditions, driven by separate underlying pathways, crosstalk between these pathways can sometimes lead to a vicious cycle of inflammation and mutually reinforced disease.<sup>2,7,9-11</sup>

Boehringer Ingelheim is committed to transforming the lives of people living with autoinflammatory diseases, such as pustular psoriasis, through understanding how faults occur in the immune system and developing treatments to blunt an overactive inflammatory response, block further damage and repair damage caused.

### Definitions:

- Agonists:** molecules that bind to a receptor to activate a biological response
- Antagonists:** molecules that bind to a receptor or a cytokine to block or inhibit a biological response
- Cytokines:** molecules involved in cell signalling and the immune response

### References:

1. Ngo Vu L, et al. *PNAS*. 2018;115(22).
2. Gabay C, et al. *J Leukoc Biol*. 2015;97(4):645-52.
3. Ganesan R, et al. *mAbs*. 2017;9:1143-54.
4. Bassoy EY, et al. *Immunol Rev*. 2018;281:169-78.
5. Marrakchi S, et al. *N Engl J Med*. 2011;365:620-8.
6. Sugiura K, et al. *J Invest Dermatol*. 2013;133:2514-21.
7. Furue K, et al. *Acta Derm Venereol*. 2018;98(1):5-13.
8. Johnston A, et al. *J Allergy Clin Immunol*. 2017 July;140(1):109-120.
9. Schön M, et al. *Front Immunol*. 2018;9:1323.
10. Pfaff CM, et al. *Sci Rep*. 2017;7:15631.
11. Liang Y, et al. *Curr Opin Immunol*. 2017;49:1-8.